Sana Biotechnology, Inc.
Sana Biotechnology, Inc. is listed today as Sana Biotechnology, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2019 | $821 M | Issued in a merger or acquisition | $250 million to $1 billion | equity | SEC | |
| Oct 2018 | $46 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Sana Biotechnology, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2020).
SEC Form D · Jun 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2020
That is all the official record says: Sana Biotechnology, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Sana Biotechnology, Inc. are on record.
Investors#
21 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Fund IX Overage, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Fund X, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Fund X Overage, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Partners IX, LLC | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Partners IX Overage, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Partners X, LLC | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Partners X, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Partners X Overage, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Flagship Pioneering Fund VI General Partner LLC | Fund or asset manager | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Flagship Pioneering Fund VI, L.P. | Fund or asset manager | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Flagship Pioneering, LLC | Fund or asset manager | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Flagship VentureLabs V LLC | Venture capital | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Flagship VentureLabs V Manager LLC | Venture capital | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Flagship Ventures Fund V General Partner LLC | Venture capital | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Flagship Ventures Fund V, L.P. | Venture capital | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Flagship V VentureLabs Rx Fund, L.P. | Venture capital | not stated | not stated | Held Series A-2 preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Geoffrey Von Maltzahn | Person | not stated | not stated | Held Series A-2 preferred stock, director (Form 3, 2021) | SEC Form 3 |
| Hans Edgar Bishop | Person | not stated | not stated | Held Series A-1, A-2 and B preferred stock, director (Form 3, 2021) | SEC Form 3 |
| James J. MacDonald | Person | not stated | not stated | Held Series A-1 preferred stock (Form 3, 2021) | SEC Form 3 |
| Steve Harr | Person | not stated | not stated | Held Series A-1, A-2 and B preferred stock, director (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 8 investors.
Largest shareholders today
Institutions holding Sana Biotechnology, Inc. shares, as of Sep 30, 2026.
- ARCH Venture Management, LLC$134 M15.31%
- FMR LLC$109 M12.45%
- Flagship Pioneering, LLC$73 M8.34%
- Ra Capital Management, L.P.$55 M6.26%
- BlackRock, Inc.$48 M5.47%
- Canada Pension Plan Investment Board$30 M3.41%
- State Street Corp$28 M3.20%
- Vanguard Capital Management LLC$25 M2.87%
- Geode Capital Management, LLC$14 M1.55%
- Bank Of America Corp /de/$14 M1.55%
- Marex Group Ltd$12 M1.33%
- Morgan Stanley$9 M1.01%
- Alphabet Inc.$8 M0.94%
- Goldman Sachs Group Inc$8 M0.89%
- Marshall Wace, LLP$7 M0.75%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| James J. MacDonald | Executive officer | Jun 2020 |
| Nathan D. Hardy | Executive officer | Jun 2020 |
| Steven D. Harr | Executive officer | Jun 2020 |
| Donald J. Payan | Director | Jun 2020 |
| Douglas J. Cole | Director | Jun 2020 |
| Geoffrey J. von Maltzahn | Director | Jun 2020 |
| Hans J. Bishop | Director | Jun 2020 |
| Mary Agnes J. Wilderotter | Director | Jun 2020 |
| Patrick J. Yang | Director | Jun 2020 |
| Richard J. Mulligan | Director | Jun 2020 |
| Robert J. Nelsen | Director | Jun 2020 |
| Stephen J. Knight | Director | Jun 2020 |
| Steven D. Harr | Director | Jun 2020 |
About
Biotechnology company.
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.